Hereditary Cancer Syndromes > CDKN2A (p16INK4a), CDKN2A (p14ARF), CDK4

Cancer Risks

Cancer Risks

Associated Syndrome

Medical Management

CDKN2A (p16INK4a)

CANCER TYPE PROCEDURE AGE TO BEGIN FREQUENCY
Melanoma Education about the importance of skin protection, such as sun avoidance, protective clothing and sunscreen. Infancy Ongoing
  Whole-body skin examinations conducted by the patient or family member. 10 years Monthly
  Clinical skin examinations by an appropriately trained provider, with consideration of whole-body photography and close-up photography of atypical nevi for ongoing comparison. 10 years Every 6 to 12 months
Pancreatic For patients with a family history of pancreatic cancer, consider available options for pancreatic cancer screening, including the possibility of endoscopic ultrasonography (EUS) and MRI/magnetic resonance cholangiopancreatography (MRCP). It is recommended that patients who are candidates for pancreatic cancer screening be managed by a multidisciplinary team with experience in the screening for pancreatic cancer, preferably within research protocols. Age 50, or 10 years younger than the earliest age of pancreatic cancer diagnosis in the family Annually
  Provide education about smoking cessation to reduce pancreatic cancer risk Individualized Individualized

CDKN2A (p14ARF)

CANCER TYPE PROCEDURE AGE TO BEGIN FREQUENCY
Melanoma Education about the importance of skin protection, such as sun avoidance, protective clothing and sunscreen. Infancy Ongoing
  Whole-body skin examinations conducted by the patient or family member. 10 years Monthly
  Clinical skin examinations by an appropriately trained provider, with consideration of whole-body photography and close-up photography of atypical nevi for ongoing comparison. 10 years Every 6 to 12 months
Pancreatic For patients with a family history of pancreatic cancer, consider available options for pancreatic cancer screening, including the possibility of endoscopic ultrasonography (EUS) and MRI/magnetic resonance cholangiopancreatography (MRCP). It is recommended that patients who are candidates for pancreatic cancer screening be managed by a multidisciplinary team with experience in the screening for pancreatic cancer, preferably within research protocols. Age 50, or 10 years younger than the earliest age of pancreatic cancer diagnosis in the family Annually
  Provide education about smoking cessation to reduce pancreatic cancer risk Individualized Individualized

CDK4

CANCER TYPE PROCEDURE AGE TO BEGIN FREQUENCY
Melanoma Education about the importance of skin protection, such as sun avoidance, protective clothing and sunscreen. Infancy Ongoing
  Whole-body skin examinations conducted by the patient or family member. 10 years Monthly
  Clinical skin examinations by an appropriately trained provider, with consideration of whole-body photography and close-up photography of atypical nevi for ongoing comparison. 10 years Every 6 to 12 months
Pancreatic Currently there are no specific medical management guidelines for pancreatic cancer risk in mutation carriers. NA NA

Unique Challenges and Issues